Fortis Healthcare Analyst Review May 2026
- May 18, 2026
- Posted by: Neeraj Pandey
- Category: News
This Fortis Healthcare analyst review for May 2026 covers the key data investors need for FORTIS at its current price of Rs 949.90. Fortis Healthcare (NSE: FORTIS) is one of India’s largest private hospital chains with a market capitalisation of approximately Rs 72,000 crore, operating over 6,300 beds across 28 hospitals. The analyst consensus target of Rs 1,150 implies meaningful upside, and this Fortis Healthcare analyst review examines technical levels, business performance, valuation, and key risks that will determine whether FORTIS achieves that target through FY27.
Click Here – Get Free Investment Predictions
Fortis Healthcare Company Snapshot May 2026
Fortis Healthcare’s speciality focus on oncology, cardiac sciences, and neuro-sciences drives premium ARPU. The IHH Healthcare (Malaysia) ownership provides financial stability and access to international best practices. The table below summarises the key data referenced in this Fortis Healthcare analyst review.
| Parameter | Value |
|---|---|
| NSE Ticker | FORTIS |
| Sector | Healthcare – Hospitals |
| CMP (May 2026) | Rs 949.90 |
| 52 Week High | Rs 1,104.30 |
| 52 Week Low | Rs 667.20 |
| Market Cap | Rs 72,000 Crore |
| Trailing P/E | 80x |
| Analyst Consensus Target | Rs 1,150 |
| Bull Case Target | Rs 1,400 |
| Bear Case Target | Rs 800 |
Analyst Insight in This Fortis Healthcare Analyst Review
Senior Research Analyst Ankit Jaiswal flags Fortis Healthcare as a stock to watch in May 2026. At Rs 949.90, Ankit Jaiswal identifies key support in the Rs 681 to Rs 902 band and resistance near Rs 1007. He suggests watching Fortis Healthcare for a potential move toward Rs 1,150, subject to Healthcare – Hospitals sector momentum and Nifty 50 direction. Ankit Jaiswal’s view is one input in this Fortis Healthcare analyst review and does not constitute a trade recommendation.
Technical Analysis in This Fortis Healthcare Analyst Review
At Rs 949.90, FORTIS is trading within its 52-week band of Rs 667.20 to Rs 1,104.30. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.
Near-term support is identified in the Rs 681 to Rs 902 band while resistance is seen in the Rs 1007 to Rs 1050 zone. A sustained move above Rs 1007 could open the path toward the analyst consensus target of Rs 1,150.
Screen the best stocks on the Univest Screener.
Key Support and Resistance Levels
- Support Zone: Rs 681 to Rs 902 – investors tracking this Fortis Healthcare analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for FORTIS.
- Resistance Zone: Rs 1007 to Rs 1050 – a sustained close above Rs 1007 would be a positive breakout signal worth flagging in this Fortis Healthcare analyst review.
- Medium-Term Target: The analyst consensus of Rs 1,150 represents the base-case upside scenario identified in this Fortis Healthcare analyst review.
Business Segment Analysis
Tertiary Care Hospitals (28 Hospitals – Pan India)
This is the primary revenue and margin driver for Fortis Healthcare, directly supporting the earnings trajectory toward the consensus target of Rs 1,150.
Oncology and Cardiac Sciences Centres
This segment adds scale and diversification to Fortis Healthcare’s business model and is a meaningful EPS contributor through FY27 and FY28.
SRL Diagnostics (Diagnostic Lab Chain)
This represents the medium-term growth frontier for Fortis Healthcare and a key re-rating catalyst for the stock over the next 12 to 24 months.
Valuation in This Fortis Healthcare Analyst Review
At Rs 949.90, Fortis Healthcare trades at a trailing P/E of 80x. This Fortis Healthcare analyst review presents three valuation scenarios: a bull case of Rs 1,400 on strong earnings delivery and sector tailwinds, a base case of Rs 1,150 at analyst consensus, and a bear case of Rs 800 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Fortis Healthcare analyst review.
| Scenario | Target Price | Key Condition |
|---|---|---|
| Bull Case | Rs 1,400 | Strong earnings delivery and sector re-rating |
| Base Case (Consensus) | Rs 1,150 | Moderate growth, analyst consensus estimate |
| Bear Case | Rs 800 | Earnings miss or macro headwinds |
Trade Outlook for Fortis Healthcare
Based on the technical and fundamental analysis in this Fortis Healthcare analyst review, investors might watch FORTIS near the support zone of Rs 681 to Rs 902 for potential opportunities. A flag above Rs 1007 could suggest improving momentum toward Rs 1,150. This article uses watch-and-flag language only and does not constitute a trade recommendation.
Key Risks for Fortis Healthcare in FY27
A well-rounded Fortis Healthcare analyst review must assess downside risks. Key risks for Fortis Healthcare include a macro slowdown affecting Healthcare – Hospitals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in FORTIS.
Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.
Conclusion: Fortis Healthcare Analyst Review Verdict for 2026
This Fortis Healthcare analyst review concludes that at Rs 949.90, FORTIS offers a defined risk-reward with a consensus target of Rs 1,150. The 52-week range of Rs 667.20 to Rs 1,104.30 provides context on the current entry point. Use this Fortis Healthcare analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on FORTIS.
Frequently Asked Questions: Fortis Healthcare Analyst Review 2026
What is the analyst target for Fortis Healthcare in 2026?
The analyst consensus target is Rs 1,150, with a bull case of Rs 1,400 and a bear case of Rs 800. Monitor Q1 FY27 earnings for confirmation as highlighted in this Fortis Healthcare analyst review.
Is Fortis Healthcare a good investment at Rs 949.90?
At Rs 949.90 with a P/E of 80x and a consensus target of Rs 1,150, this Fortis Healthcare analyst review is constructive for medium to long-term investors in the Healthcare – Hospitals sector. Always consult a SEBI-registered advisor before investing.
What is Fortis Healthcare’s 52-week high and low?
The 52-week high is Rs 1,104.30 and the 52-week low is Rs 667.20. At Rs 949.90, FORTIS is positioned within this range as noted in this Fortis Healthcare analyst review.
What are the key risks for Fortis Healthcare?
Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Healthcare – Hospitals sector as assessed in this Fortis Healthcare analyst review.
Where can I track live data for Fortis Healthcare?
Track Fortis Healthcare’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Fortis Healthcare analyst review.
Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.
